Journal of diabetes investigation · 2025
Outcomes of insulin treatment using an automated insulin delivery system from the onset of type 1 diabetes in pediatric patients-A 1-year retrospective, observational, two-center study.
СтатьяНаблюдательное исследованиеМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tarasiewicz Mateusz, Chobot Agata, Bielawska Anna, Zając Agnieszka, Polańska Joanna, Jarosz-Chobot Przemysława, Seget Sebastian
Аннотация
INTRODUCTION: MiniMed 780G was the first automated insulin delivery (AID) system approved in Poland. Although it has been studied extensively, there are relatively less data regarding its use in children with type 1 diabetes from the onset of the disease. We aimed to evaluate and compare glycemic parameters in children treated from type 1 diabetes onset with either an AID system or a pump with predictive-low glucose suspend (SAP-PLGS).
MATERIAL AND METHODS: We retrospectively gathered anthropometric data and systems records of 50 children with a newly diagnosed type 1 diabetes, 22 using an AID system (aged 9.66 ± 3.76 years), and 28 using a SAP-PLGS device (aged 8.13 ± 4.2 years). Glycemic parameters and other collected data were compared at four different time points: the first 2 weeks using the insulin pump and 2 weeks after 3, 6, and 12 months of insulin therapy.
RESULTS: After the first year of treatment, we found in the AID group higher time in range (TIR) 70-180 mg/dL (P = 0.001) as well as time in tight range (TITR) 70-140 mg/dL (P = 0.0003). There were no significant differences in the C-peptide level after 1 year of treatment between the two studied groups (P = 0.41).
CONCLUSIONS: Using the AID system from the onset of type 1 diabetes resulted in improved glycemic control parameters in the studied children compared with using SAP-PLGS. The C-peptide preservation was comparable in both analyzed groups.
MATERIAL AND METHODS: We retrospectively gathered anthropometric data and systems records of 50 children with a newly diagnosed type 1 diabetes, 22 using an AID system (aged 9.66 ± 3.76 years), and 28 using a SAP-PLGS device (aged 8.13 ± 4.2 years). Glycemic parameters and other collected data were compared at four different time points: the first 2 weeks using the insulin pump and 2 weeks after 3, 6, and 12 months of insulin therapy.
RESULTS: After the first year of treatment, we found in the AID group higher time in range (TIR) 70-180 mg/dL (P = 0.001) as well as time in tight range (TITR) 70-140 mg/dL (P = 0.0003). There were no significant differences in the C-peptide level after 1 year of treatment between the two studied groups (P = 0.41).
CONCLUSIONS: Using the AID system from the onset of type 1 diabetes resulted in improved glycemic control parameters in the studied children compared with using SAP-PLGS. The C-peptide preservation was comparable in both analyzed groups.